Ng R, Pond G R, Tang P A, MacIntosh P W, Siu L L, Chen E X
Department of Medical Oncology and Hematology, Princess Margaret Hospital, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Ann Oncol. 2008 Mar;19(3):481-6. doi: 10.1093/annonc/mdm486. Epub 2007 Nov 20.
Although disease-free survival (DFS) is accepted as a valid end point in adjuvant breast cancer trials, improvement in 2-year DFS has never been formally established as an adequate correlate for 5-year overall survival (OS). We set out to ascertain if changes in 2-year DFS can be used to accurately predict 5-year OS changes.
We conducted a systematic Medline search (1966-2006) for randomized adjuvant breast cancer trials of >100 patients per arm with 2-year DFS and 5-year OS data. A univariate regression model weighted by trial sample size was constructed to determine whether 2-year DFS differences between treatment arms within trials were predictive of 5-year OS differences.
A total of 126 studies containing 149 treatment comparisons met the inclusion criteria. Difference in 2-year DFS was a significant predictor of difference in 5-year OS. For every 1% increase in 2-year DFS difference, the 5-year OS difference increased by 0.5%-0.55%. The proportion of variation explained ranged from 0.38 to 0.42, with a wide prediction interval.
There is a statistically significant correlation, of moderate strength, between difference in 2-year DFS between treatment comparisons and difference in 5-year OS but the correlation is not strong enough to be used as a predictor.
尽管无病生存期(DFS)被公认为辅助性乳腺癌试验中的一个有效终点,但2年DFS的改善从未被正式确立为5年总生存期(OS)的充分关联指标。我们着手确定2年DFS的变化是否可用于准确预测5年OS的变化。
我们对Medline进行了系统检索(1966 - 2006年),以查找每组超过100例患者且有2年DFS和5年OS数据的随机辅助性乳腺癌试验。构建了一个按试验样本量加权的单变量回归模型,以确定试验中各治疗组之间的2年DFS差异是否能预测5年OS差异。
共有126项研究包含149个治疗组比较符合纳入标准。2年DFS的差异是5年OS差异的显著预测指标。2年DFS差异每增加1%,5年OS差异增加0.5% - 0.55%。解释的变异比例范围为0.38至0.42,预测区间较宽。
治疗组比较之间的2年DFS差异与5年OS差异之间存在统计学上显著的、中等强度的相关性,但该相关性不够强,不足以用作预测指标。